miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial–Mesenchymal Transition

Pemetrexed is a folic acid inhibitor used as a second-line chemotherapeutic agent for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancers. However, prolonged treatment with pemetrexed may cause cancer cells to develop resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Wen-Wei, Wang, Bing-Yen, Chen, Shih-Hong, Chien, Peng-Ju, Sheu, Gwo-Tarng, Lin, Ching-Hsiung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741456/
https://www.ncbi.nlm.nih.gov/pubmed/36499676
http://dx.doi.org/10.3390/ijms232315352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741456/
https://www.ncbi.nlm.nih.gov/pubmed/36499676
http://dx.doi.org/10.3390/ijms232315352

Ejemplares similares